News | 3-D Printing | April 18, 2017

3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization

A 3-D-printed phantom of a stenotic artery is enabling a global collaborative to standardize vessel-wall MRI protocols for intracranial atherosclerotic disease, laying the groundwork for multisite trials of new therapies.

3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization

April 18, 2017 — A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the University of Massachusetts has led to the creation of a realistic, 3-D-printed phantom of a stenotic intracranial artery. The phantom is being used to standardize protocols for high-resolution magnetic resonance imaging (MRI), also known as vessel-wall MRI, at a network of U.S. and Chinese institutions, according to an article published online by the Journal of NeuroInterventional Surgery.

High-resolution or vessel-wall MRI has been used to study the plaque components in vessels in the brain for more than ten years and has the potential to elucidate the underlying pathology of intracranial atherosclerotic disease (ICAD), the leading cause of stroke worldwide, as well as to gauge patient risk and inform clinical trials of new therapies. However, progress has been stymied by the lack of standardization in high-resolution MRI protocols, which poses an obstacle to multicenter trials.

"There is a lot of exciting research that is possible with high-resolution MRI techniques, but it has much less opportunity to affect patient care if it can't be systematically distributed to multiple sites and multiple populations," said Tanya N. Turan, M.D., director of the MUSC Stroke Division and senior author of the article.

To overcome this obstacle, Turan worked with bioengineers at the University of Massachusetts to produce a phantom of a stenotic intracranial vessel using imaging sequences obtained from a single patient with ICAD at MUSC. The 3-D printed ICAD phantom mimics both the stenotic vessel and its plaque components, including the fibrous cap and the lipid core. The phantom is being shared with collaborating institutions so that it can be used to standardize high-resolution MRI protocols. The imaging data presented in the Journal of NeuroInterventional Surgery article demonstrate the feasibility of using the phantom for standardization and were obtained from six U.S. and two Chinese sites.

Producing the phantom was a major step in the right direction for standardizing high-resolution MRI ICAD protocols. However, several more years may be necessary to complete the process. The next major challenge for these investigators will be establishing parameters for MRI machines from a variety of manufacturers. So far, MRI parameters have been established for Siemens and GE systems but work is still under way on Philips systems.

The phantom is also being shared with sites in China, where the burden of intracranial stenosis is especially high. Turan is collaborating with Weihai Xu, M.D., of Peking Union Medical College, the lead Chinese site, to collect additional data to assess interrater reliability among the participating institutions. Once high-resolution MRI protocols have been standardized and good interrater reliability demonstrated, the international team plans to conduct a prospective observational trial to examine risk prediction at participating centers, which would more quickly meet the required patient enrollment than would a trial conducted in the U.S. alone.

"We're only going to be able to advance the field more quickly if we work together," said Turan. "The phantom gives us the tool to be able to work together."

For more information: www.jnis.bmj.com

Related Content

Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
FDA Clears Siemens Magnetom Terra 7T MRI Device

The FDA has cleared the Siemens Magnetom Terra as the first 7T MRI system in the U.S. to gain regulatory approval.

Technology | Magnetic Resonance Imaging (MRI)| October 12, 2017
The U.S. Food and Drug Administration (FDA) cleared the first 7 Tesla (7T) magnetic resonance imaging (MRI) device,...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI)| October 11, 2017
MR Solutions took their cryogen-free preclinical multimodality magnetic resonance imaging (MRI) solutions on tour in...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Majority of High-Risk Stroke Patients Not Being Screened for Common Risk Factors
News | Stroke| September 28, 2017
September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwid
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init